MedTrace Logo

Vaccine Therapy in Treating Patients With Recurrent B-Cell Lymphoma

NCT00561756 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2015-11-17

No results posted yet for this study

Summary

RATIONALE: Vaccines made from mouse DNA may help the body build an effective immune response to kill cancer cells.

PURPOSE: This phase I trial is studying the side effects and best dose of mouse DNA vaccine in treating patients with recurrent B-cell lymphoma.

Conditions

Interventions

BIOLOGICAL

plasmid DNA vaccine therapy

OTHER

flow cytometry

OTHER

immunoenzyme technique

Sponsors & Collaborators

Principal Investigators

  • M. Lia Palomba, MD · Memorial Sloan Kettering Cancer Center

  • Andrew D. Zelenetz, MD, PhD · Memorial Sloan Kettering Cancer Center

  • Alan N. Houghton, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00561756 on ClinicalTrials.gov